

Attorney Docket No. 47992/58118 (formerly NIH-05065)
U.S.S.N.: 09/597,920
Filed: June 19, 2000.
Amendment and Response to Final Office Action
Page 2 of 16

CDM8 and poly(A) adenylation site, respectively. The slashed areas in the EF-1 α promoter region represent sequences from the first exon and part of the second exon, respectively. The lines flanking the boxes are sequences from pUC119. Major recognition sites for restriction enzymes are shown.--

Please delete pages 37 and 60, and renumber the remaining pages as appropriate.

In the Claims

Please cancel claims 40 and 42-60.

Please add claims 61-78.

Please amend claim 4, 39 and 41.

4. (Amended) A purified antibody which is generated against a polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO: 4 and which specifically binds to a LAT polypeptide comprising an amino acid sequence according to SEQ ID NO: 4, but which does not cross-react with non-LAT ZAP 70 or non-LAT Syk substrates.
39. (Amended) The purified antibody of any of Claims 4-6, wherein said polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO: 4 comprises the cytosolic tail of LAT.
41. (Amended) The purified antibody of any of Claims 4-6, wherein said polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO: 4 comprises amino acids 31-233 of LAT.

Attorney Docket No. 47992/58118 (formerly NIII-05065)
U.S.S.N.: 09/597,920
Filed: June 19, 2000.
Amendment and Response to Final Office Action
Page 3 of 16

61. (New) A purified antibody which is generated against a polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO: 4, wherein the at least a portion of the amino acid sequence comprises a phosphotyrosine residue and wherein the antibody specifically binds to a phosphorylated LAT polypeptide comprising an amino acid sequence according to SEQ ID NO: 4, but which does not cross-react with other non-LAT ZAP 70 or non-LAT Syk substrates.
62. (New) The purified antibody of Claim 61, wherein the at least a portion comprises at least about 5 amino acids of SEQ ID NO. 4.
63. (New) The purified antibody of Claim 61, wherein the at least a portion comprises at least about 20 amino acids of SEQ ID NO. 4.
64. (New) The purified antibody of Claim 61, wherein the at least a portion comprises of SEQ ID NO. 4.
65. (New) The purified antibody of any of Claims 61-64, wherein the antibody is a polyclonal antibody.
66. (New) The purified antibody of any of Claims 61-64, wherein the antibody is a monoclonal antibody.
67. (New) A purified antibody which is generated against a polypeptide comprising at least about five amino acids of the amino acid sequence of SEQ ID NO: 4 and which specifically binds to a LAT polypeptide comprising an amino acid sequence according to SEQ ID NO: 4.

Attorney Docket No. 47992/58118 (formerly NIH-05065)

U.S.S.N.: 09/597,920

Filed: June 19, 2000.

Amendment and Response to Final Office Action

Page 4 of 16

68. (New) The purified antibody of Claim 67, wherein the polypeptide comprising at least about five amino acids comprises at least about 20 amino acids of SEQ ID NO: 4.
69. (New) The purified antibody of Claim 67, wherein the polypeptide comprising at least about five amino acids comprises SEQ ID NO: 4.
70. (New) The purified antibody of Claim 68, wherein said polypeptide comprising at least about twenty amino acids of the amino acid sequence of SEQ ID NO: 4 comprises the cytosolic tail of LAT.
71. (New) The purified antibody of Claims 70, wherein said polypeptide comprising at least about twenty amino acids of the amino acid sequence of SEQ ID NO: 4 comprises amino acids 31-233 of LAT.
72. (New) The purified antibody of any of Claims 67-71, wherein the antibody is a polyclonal antibody.
73. (New) The purified antibody of any of Claims 67-71, wherein the antibody is a monoclonal antibody.
74. (New) A purified antibody which is generated against a polypeptide comprising at least about five amino acids of the amino acid sequence of SEQ ID NO: 4, wherein the at least about five amino acids comprises a phosphotyrosine residue and wherein the antibody specifically binds to a phosphorylated LAT polypeptide comprising an amino acid sequence according to SEQ ID NO: 4.
75. (New) The purified antibody of claim 74, wherein the polypeptide comprising at least about five amino acids comprises at least about 20 amino acids of SEQ ID NO: 4.

Attorney Docket No. 47992/58118 (formerly NIH-05065)
U.S.S.N.: 09/597,920
Filed: June 19, 2000.
Amendment and Response to Final Office Action
Page 13 of 16

Attorney Docket No. 47992/58118 (formerly NIH-05065)
U.S.S.N.: 09/597,920
Filed: June 19, 2000.

PENDING CLAIMS UPON ENTRY OF AMENDMENT

4. (Amended) A purified antibody which is generated against a polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO: 4 and which specifically binds to a LAT polypeptide comprising an amino acid sequence according to SEQ ID NO: 4, but which does not cross-react with other non-LAT ZAP 70 or non-LAT Syk substrates.
5. A purified antibody of Claim 4, wherein said antibody is a polyclonal antibody.
6. The purified antibody of Claim 4, wherein said antibody is a monoclonal antibody.
29. The purified antibody of claim 4, wherein said antibody is directed against SEQ ID NO:4.
33. The purified antibody of claim 5, wherein the antibody is directed against SEQ ID NO: 4.
37. The purified antibody of Claim 6, wherein said antibody is directed against SEQ ID NO:4.
38. The purified antibody of Claim 4, wherein said portion comprises at least 20 amino acids of SEQ ID NO: 4.
39. (Amended) The purified antibody of any of Claims 4-6, wherein said polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO: 4 comprises the

Attorney Docket No. 47992/58118 (formerly NIH-05065)
U.S.S.N.: 09/597,920
Filed: June 19, 2000.
Amendment and Response to Final Office Action
Page 14 of 16

cytosolic tail of LAT.

41. (Amended) The purified antibody of any of Claims 4-6, wherein said polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO: 4 comprises amino acids 31-233 of LAT.
61. (New) A purified antibody which is generated against a polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO: 4, wherein the at least a portion of the amino acid sequence comprises a phosphotyrosine residue and wherein the antibody specifically binds to a phosphorylated LAT polypeptide comprising an amino acid sequence according to SEQ ID NO: 4, but which does not cross-react with other non-LAT ZAP 70 or non-LAT Syk substrates.
62. (New) The purified antibody of Claim 61, wherein the at least a portion comprises at least about 5 amino acids of SEQ ID NO. 4.
63. (New) The purified antibody of Claim 61, wherein the at least a portion comprises at least about 20 amino acids of SEQ ID NO. 4.
64. (New) The purified antibody of Claim 61, wherein the at least a portion comprises of SEQ ID NO. 4.
65. (New) The purified antibody of any of Claims 61-64, wherein the antibody is a polyclonal antibody.
66. (New) The purified antibody of any of Claims 61-64, wherein the antibody is a monoclonal antibody.

Attorney Docket No. 47992/58118 (formerly NIH-05065)
U.S.S.N.: 09/597,920
Filed: June 19, 2000.
Amendment and Response to Final Office Action
Page 15 of 16

67. (New) A purified antibody which is generated against a polypeptide comprising at least about five amino acids of the amino acid sequence of SEQ ID NO: 4 and which specifically binds to a LAT polypeptide comprising an amino acid sequence according to SEQ ID NO: 4.
68. (New) The purified antibody of Claim 67, wherein the polypeptide comprising at least about five amino acids comprises at least about 20 amino acids of SEQ ID NO: 4.
69. (New) The purified antibody of Claim 67, wherein the polypeptide comprising at least about five amino acids comprises SEQ ID NO: 4.
70. (New) The purified antibody of Claim 68, wherein said polypeptide comprising at least about twenty amino acids of the amino acid sequence of SEQ ID NO: 4 comprises the cytosolic tail of LAT.
71. (New) The purified antibody of Claims 70, wherein said polypeptide comprising at least about twenty amino acids of the amino acid sequence of SEQ ID NO: 4 comprises amino acids 31-233 of LAT.
72. (New) The purified antibody of any of Claims 67-71, wherein the antibody is a polyclonal antibody.
73. (New) The purified antibody of any of Claims 67-71, wherein the antibody is a monoclonal antibody.
74. (New) A purified antibody which is generated against a polypeptide comprising at least about five amino acids of the amino acid sequence of SEQ ID NO: 4, wherein the at least about five amino acids comprises a phosphotyrosine residue and wherein the antibody

Attorney Docket No. 47992/58118 (formerly NIH-05065)
U.S.S.N.: 09/597,920
Filed: June 19, 2000.
Amendment and Response to Final Office Action
Page 16 of 16

specifically binds to a phosphorylated LAT polypeptide comprising an amino acid sequence according to SEQ ID NO: 4.

75. (New) The purified antibody of claim 74, wherein the polypeptide comprising at least about five amino acids comprises at least about 20 amino acids of SEQ ID NO: 4.
76. (New) The purified antibody of claim 74, wherein the polypeptide comprising at least about five amino acids comprises SEQ ID NO: 4.
77. (New) The purified antibody of any of Claims 74-76, wherein the antibody is a polyclonal antibody.
78. (New) The purified antibody of any of Claims 74-76, wherein the antibody is a monoclonal antibody.

BOS2_319699.1